aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Company profile
Ticker
ACRS
Exchange
Website
CEO
Neal Walker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aclaris Life Sciences, Inc. • Confluence Discovery Technologies, Inc. ...
ACRS stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
27 Feb 24
8-K/A
Departure of Directors or Certain Officers
5 Feb 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
8-K
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
19 Jan 24
8-K
Aclaris Therapeutics Provides Corporate Update
19 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
6 Nov 23
Transcripts
ACRS
Earnings call transcript
2023 Q1
8 May 23
ACRS
Earnings call transcript
2019 Q4
25 Feb 20
ACRS
Earnings call transcript
2019 Q3
10 Nov 19
ACRS
Earnings call transcript
2019 Q2
9 Aug 19
ACRS
Earnings call transcript
2019 Q1
9 May 19
ACRS
Earnings call transcript
2018 Q4
18 Mar 19
ACRS
Earnings call transcript
2018 Q3
11 Nov 18
ACRS
Earnings call transcript
2018 Q2
3 Aug 18
ACRS
Earnings call transcript
2018 Q1
13 May 18
ACRS
Earnings call transcript
2017 Q4
12 Mar 18
Latest ownership filings
4
Neal Walker
3 Apr 24
4
Neal Walker
5 Mar 24
4
Joseph Monahan
5 Mar 24
4
Kevin Balthaser
5 Mar 24
4
Andrew Kenneth William Powell
5 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
MILLENNIUM MANAGEMENT LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 39.04 mm | 39.04 mm | 39.04 mm | 39.04 mm | 39.04 mm | 39.04 mm |
Cash burn (monthly) | (no burn) | 1.88 mm | 10.53 mm | 10.20 mm | 8.19 mm | 7.56 mm |
Cash used (since last report) | n/a | 12.81 mm | 71.54 mm | 69.32 mm | 55.64 mm | 51.36 mm |
Cash remaining | n/a | 26.23 mm | -32.50 mm | -30.28 mm | -16.60 mm | -12.32 mm |
Runway (months of cash) | n/a | 13.9 | -3.1 | -3.0 | -2.0 | -1.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 137 |
Opened positions | 13 |
Closed positions | 29 |
Increased positions | 52 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 723.14 bn |
Total shares | 80.67 mm |
Total puts | 1.43 mm |
Total calls | 1.18 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Wellington Management | 7.64 mm | $79.20 bn |
BLK Blackrock | 5.59 mm | $58.01 bn |
Ra Capital Management | 4.40 mm | $45.61 bn |
Rock Springs Capital Management | 3.96 mm | $41.08 bn |
Bain Capital Life Sciences Investors | 3.40 mm | $35.26 bn |
Foresite Capital Fund III | 3.40 mm | $49.42 mm |
Biotechnology Value Fund L P | 3.36 mm | $23.76 mm |
BVF | 3.36 mm | $34.85 bn |
Vanguard | 3.33 mm | $34.53 bn |
Braidwell | 2.90 mm | $30.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Neal Walker | Common Stock | Payment of exercise | Dispose F | No | No | 1.26 | 3,224 | 4.06 k | 1,285,688 |
1 Apr 24 | Neal Walker | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,467 | 0.00 | 1,288,912 |
1 Apr 24 | Neal Walker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,467 | 0.00 | 123,067 |
4 Mar 24 | Andrew Kenneth William Powell | Common Stock | Buy | Acquire P | No | No | 1.25 | 6,000 | 7.50 k | 28,863 |
2 Mar 24 | Joseph Monahan | Common Stock | Payment of exercise | Dispose F | No | No | 1.24 | 3,531 | 4.38 k | 186,783 |
2 Mar 24 | Joseph Monahan | Common Stock | Option exercise | Acquire M | No | No | 0 | 12,500 | 0.00 | 190,314 |
2 Mar 24 | Joseph Monahan | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 12,500 | 0.00 | 0 |
2 Mar 24 | Kevin Balthaser | Common Stock | Payment of exercise | Dispose F | No | No | 1.24 | 427 | 529.48 | 23,983 |
2 Mar 24 | Kevin Balthaser | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,500 | 0.00 | 24,410 |
2 Mar 24 | Kevin Balthaser | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,500 | 0.00 | 0 |